Welcome to our dedicated page for 111 news (Ticker: YI), a resource for investors and traders seeking the latest updates and insights on 111 stock.
111, Inc. reports on a China-based, tech-enabled healthcare platform that connects consumers, pharmacies and healthcare partners through online and offline channels. The company’s recurring updates cover its B2B pharmaceutical sourcing platform, B2C online retail pharmacy activity, internet hospital services through 1 Clinic, and cloud-based services for offline pharmacies.
Company news also focuses on unaudited financial results, gross segment profit, operating expenses, cash flow, B2B gross margin trends and the transition toward an asset-light fulfillment partnership model. Other recurring topics include digital tools, supply-chain efficiency, drug commercialization services and Nasdaq ADR listing compliance matters.
111, Inc. (NASDAQ: YI) announced the completion of a RMB419.82 million (approx. US$60.49 million) capital injection into its principal subsidiary, Yao Fang Shanghai, at a pre-money valuation of US$1.2 billion. The funding aims to enhance the company’s financial flexibility and support plans to list Yao Fang Shanghai on the STAR Market within three years. This strategic move is designed to provide access to new capital and strengthen its position in China's digital healthcare market. The investors have the option to redeem their equity if the listing does not proceed within the specified timeframe.
111, Inc. (NASDAQ: YI) will release its unaudited financial results for the second quarter ending June 30, 2020, before the U.S. market opens on August 20, 2020. An earnings conference call is scheduled for 7:30 AM ET on the same day. The company connects patients with drugs and healthcare services across China through its online platforms and offline network. Interested participants must register online to join the call, and a replay will be available until August 28, 2020. More information can be found on the company’s investor relations website.